The role of hydroxychloroquine in COVID-19: Where do we stand?
| Autor: | Tata Sameer Nandan, Ranjit Unnikrishnan, Gangadhara Praveen, Jaggi Shalini, Muthu Ramuu, Prasanna Kumar Gupta, Nadiminty Ganapathi Sastry, Routray Philips, Chaithanya Murthy Kocherlakota, Viswanathan Mohan, Ranjit Mohan Anjana, Jyotish Nair, Brijendra Kumar Srivastava |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
hydroxychloroquine lcsh:RC648-665 treatment Coronavirus disease 2019 (COVID-19) business.industry Hydroxychloroquine medicine.disease lcsh:Diseases of the endocrine glands. Clinical endocrinology Dermatology coronavirus disease 2019 Rheumatoid arthritis Pandemic medicine General Earth and Planetary Sciences skin and connective tissue diseases business Malaria General Environmental Science medicine.drug |
| Zdroj: | Journal of Diabetology, Vol 11, Iss 2, Pp 65-70 (2020) |
| ISSN: | 2078-7685 |
| DOI: | 10.4103/jod.jod_33_20 |
| Popis: | Hydroxychloroquine (HCQ) is a drug, which has long been used in the treatment of malaria, rheumatoid arthritis, systemic lupus erythematosus, and Sjogren’s syndrome. Recently with the COVID-19 pandemic hitting the world, there have been studies suggesting that hydroxychloroquine may be useful both in the prevention and the treatment of COVID-19, although the evidence so far has been conflicting. This article reviews the available evidence for the use of hydroxychloroquine in COVID-19 and also mentions some of the ongoing trials in this field. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|